Immutep Stock Price, News & Analysis

Immutep Limited (ASX: IMM; NASDAQ: IMMP) has made significant advancements in its clinical development strategy for the quarter ending March 31, 2023. The company initiated the AIPAC-003 Phase II/III trial for eftilagimod alpha (efti) in HER2-negative and triple-negative metastatic breast cancer, with the first patient enrollment expected in Q2 2023. Positive final data from the TACTI-002 trial showed a 39% overall survival rate at 21 months for patients with second-line non-small cell lung cancer (NSCLC). The TACTI-003 trial reached 75% enrollment, and top-line results are anticipated in H2 2023. Furthermore, the INSIGHT-003 trial's expansion aims to evaluate a triple combination therapy in NSCLC. Immutep maintains a robust cash position of A$55.2 million, providing a runway until June 2024.

Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced the presentation of final results from the Phase II TACTI-002 trial, focusing on patients with second-line head and neck squamous cell carcinoma. The results will be showcased at the 2023 ASCO Annual Meeting, which takes place from June 2-6 in Chicago, Illinois. The trial evaluates the combination of eftilagimod alpha and pembrolizumab in patients who are unselected for PD-L1 expression. Additionally, the trial design for the Phase II/III AIPAC-003 study, which tests eftilagimod alpha in HER2-negative metastatic breast cancer, will also be presented. Key presentation details include poster sessions on June 4 and 5. This opportunity allows Immutep to engage with leading oncology experts and gain visibility for its innovative therapies.